UroGen Pharma Ltd. - Ordinary Shares (URGN): Price and Financial Metrics


UroGen Pharma Ltd. - Ordinary Shares (URGN)

Today's Latest Price: $21.64 USD

1.31 (-5.71%)

Updated Oct 20 4:00pm

Add URGN to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

URGN Stock Summary

  • URGN's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.21 -- higher than only 4.45% of US-listed equities with positive expected earnings growth.
  • With a price/sales ratio of 1,358.73, UroGen Pharma Ltd has a higher such ratio than 99.52% of stocks in our set.
  • As for revenue growth, note that URGN's revenue has grown 1,966.67% over the past 12 months; that beats the revenue growth of 99.46% of US companies in our set.
  • Stocks that are quantitatively similar to URGN, based on their financial statements, market capitalization, and price volatility, are NYMX, OCX, PTN, PRTA, and CRMD.
  • Visit URGN's SEC page to see the company's official filings. To visit the company's web site, go to www.urogen.com.

URGN Stock Price Chart Interactive Chart >

Price chart for URGN

URGN Price/Volume Stats

Current price $21.64 52-week high $35.21
Prev. close $22.95 52-week low $13.12
Day low $21.32 Volume 122,500
Day high $23.11 Avg. volume 192,661
50-day MA $21.65 Dividend yield N/A
200-day MA $24.35 Market Cap 452.21M

UroGen Pharma Ltd. - Ordinary Shares (URGN) Company Bio


UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing therapies for urological pathologies. The company is developing its product candidates as chemoablation agents, which are designed to remove tumors by non-surgical means, to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma, and low-grade bladder cancer. The company was founded in 2004 and is based in Raanana, Israel.


URGN Latest News Stream


Event/Time News Detail
Loading, please wait...

URGN Latest Social Stream


Loading social stream, please wait...

View Full URGN Social Stream

Latest URGN News From Around the Web

Below are the latest news stories about UroGen Pharma Ltd that investors may wish to consider to help them evaluate URGN as an investment opportunity.

UroGen's Phase 2 RTGel combo study for OAB misses primary endpoint

UroGen (URGN) -3.8% in premarket, says Phase 2 trial of RTGel hydrogel formulation in combination with Botox did not meet the primary endpoint of improvement of overactive bladder ((OAB)) symptoms, as measured by the reduction in urinary incontinence episodes per day. The data suggests result may have been because of Botox not effectively...

Seeking Alpha | August 27, 2020

UroGen Pharma to Report Second Quarter 2020 Financial Results on Monday, August 10, 2020

UroGen Pharma Ltd. (Nasdaq:URGN), a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases

Business Wire | August 3, 2020

Hedge Funds Are Selling UroGen Pharma Ltd. (URGN)

The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […]

Yahoo | June 16, 2020

UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

UroGen Pharma Ltd. (Nasdaq:URGN) a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced the grants of inducement restricted stock units ("RSUs") on June 3, 2020 to eight new employees in connection with their employment with UroGen. These new team members will support the Company’s commercial launch of JelmytoTM (mitomycin) for pyelocalyceal solution, its first approved product.

Yahoo | June 5, 2020

UroGen Pharma (URGN) Presents At Jefferies Healthcare Conference - Slideshow

The following slide deck was published by UroGen Pharma Ltd. in conjunction with this event....

SA Transcripts | June 3, 2020

Read More 'URGN' Stories Here

URGN Price Returns

1-mo 7.45%
3-mo -10.28%
6-mo -10.54%
1-year -0.64%
3-year -20.67%
5-year N/A
YTD -35.15%
2019 -22.50%
2018 15.72%
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 1.2199 seconds.